Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 10, 2007, Pages 2874-2878

  KrennHrubec, Keris ^a   Marshall, Brett L ^b   Hedglin, Mark ^a   Verdin, Eric ^b   Ulrich, Scott M ^a  

^a ITHACA COLLEGE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HDAC8; Histone deacetylases; Hydroxamic acids

Indexed keywords

ENZYME INHIBITOR; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE 8 INHIBITOR; HYDROXAMIC ACID; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT;

ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50;

CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ENZYME INHIBITORS; HELA CELLS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN CONFORMATION; REPRESSOR PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34247376560     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.02.064     Document Type: Article

References (22)

1. Kornberg R.D., and Lorch Y. Cell 98 (1999) 285
2. Jenuwein T., and Allis C.D. Science 293 (2001) 1074
3. Peterson C.L., and Laniel M.A. Curr. Biol. 14 (2004) R546
4. Struhl K. Gene Dev. 12 (1998) 599
5. Hecht A., Laroche T., Strahl-Bolsinger S., Gasser S.M., and Grunstein M. Cell 80 (1995) 583
6. Shogren-Knaak M., Ishii H., Sun J.M., Pazin M.J., Davie J.R., and Peterson C.L. Science 311 (2006) 844
7. North B.J., Marshall B.L., Borra M.T., Denu J.M., and Verdin E. Mol. Cell 11 (2003) 437
8. Hubbert C., Guardiola A., et al. Nature 417 (2002) 455
9. Holbert M.A., and Marmorstein R. Curr. Opin. Struct. Biol. 15 (2005) 673
10. Marks P.A., Richon V.M., Miller T., and Kelly W.K. Adv. Cancer Res. 91 (2004) 137
11. Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., Breslow R., and Pavletich N.P. Nature 401 (1999) 188
12. Nielsen T.K., Hildmann C., Dickmanns A., Schwienhorst A., and Ficner R. J. Mol. Biol. 354 (2005) 107
13. Somoza J.R., Skene R.J., Katz B.A., Mol C., Ho J.D., Jennings A.J., Luong C., Arvai A., Buggy J.J., Chi E., Tang J., Sang B.C., Verner E., Wynands R., Leahy E.M., Dougan D.R., Snell G., Navre M., Knuth M.W., Swanson R.V., McRee D.E., and Tari L.W. Structure 12 (2004) 1325
14. Sternson S.M., Wong J.C., Grozinger C.M., and Schreiber S.L. Org. Lett. 3 (2001) 4239
15. Haggarty S.J., Koeller K.M., Wong J.C., Grozinger C.M., and Schreiber S.L. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 4389
16. Hu E., et al. J. Pharmacol. Exp. Ther. 307 (2003) 720
17. Waltregny D., De Leval L., Glenisson W., Ly Tran S., North B.J., Bellahcene A., Weidle U., Verdin E., and Castronovo V. Am. J. Pathol. 165 (2004) 553
18. Waltregny D., Glenisson W., Tran S.L., North B.J., Verdin E., Colige A., and Castronovo V. FASEB J. 19 (2005) 966
19. Durst K.L., Lutterbach B., Kummalue T., Friedman A.D., and Hiebert S.W. Mol. Cell. Biol. 23 (2003) 607
20. Summers J.B., Mazdiyasni H., Holms J.H., Ratajczyk J.D., Dyer R.D., and Carter G.W. J. Med. Chem. 30 (1987) 574
21. -6) δ = 164.54, 143.30, 139.16, 133.94, 132.33, 131.11, 130.34, 128.98, 128.60, 127.61, 127.52, 127.12, 126.60, 126.12, 125.55 ppm.
22. Verdin E., Dequiedt F., Fischle W., Frye R., Marshall B., and North B. Methods Enzymol. 377 (2004) 180